We bring you the latest news from the healthcare about the health care in the United Kingdom.

zaterdag 13 januari 2018

The Lancet: [Comment] Considering quantity and quality of life in metastatic castration-naive prostate cancer

[Comment] Considering quantity and quality of life in metastatic castration-naive prostate cancer
The treatment approach for metastatic prostate cancer is rapidly evolving. Drugs that were previously used primarily in the setting of castration-resistant prostate cancer have now been shown to improve survival in castration-naive disease. Specifically, both abiraterone acetate (in combination with prednisone)1,2 and docetaxel3 have been shown to confer an overall survival advantage when used with androgen deprivation therapy (ADT) in patients with metastatic castration-naive prostate cancer. Although these are promising developments, it is important that these treatments improve both quantity and quality of life in patients.
Read more

[Comment] A new era for treatment development in HER2-positive breast cancer
HER2-positive breast cancer has long been considered a clinically distinct disease, mainly because of the striking efficacy achieved by HER2-targeted treatments in the early and metastatic settings. However, the effectiveness of these therapies has been variable, and the development of different types of treatment resistance reveals the diversity of HER2-positive breast cancers. As part of efforts by the International Cancer Genome Consortium (ICGC) Breast Cancer Working Group, Ferrari and colleagues1 established the gene expression profiles of HER2-positive breast tumours.
Read more

[Articles] Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
Patients with young-onset breast cancer who carry a BRCA mutation have similar survival as non-carriers. However, BRCA mutation carriers with triple-negative breast cancer might have a survival advantage during the first few years after diagnosis compared with non-carriers. Decisions about timing of additional surgery aimed at reducing future second primary-cancer risks should take into account patient prognosis associated with the first malignancy and patient preferences.
Read more

[Comment] Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?
Young women with breast cancer have always caught the attention of both clinicians and researchers, despite this group being a rarity. Several factors distinguish the biology of both breast cancer in young patients and the patients themselves from that of tumours and patients who are diagnosed later in life. Additionally, the cancers might be associated with a previous pregnancy or have a pathogenesis that is based on a genetic predisposition; some data even imply that both cancers associated with a previous pregnancy and a genetic predisposition to cancer might be directly connected.
Read more

[Articles] Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
Venetoclax plus hypomethylating agent therapy seems to be a novel, well-tolerated regimen with promising activity in this underserved patient population. Evaluation of expansion cohorts is ongoing at 400 mg and 800 mg doses using both hypomethylating agent combinations.
Read more